caa a22 4500 445338628 CHVBK 20180317142804.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1245/s10434-011-2086-4 doi (NATIONALLICENCE)springer-10.1245/s10434-011-2086-4 Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer [Elektronische Daten] [Yun Chun, Harry Cooper, Steven Cohen, Andre Konski, Barbara Burtness, Crystal Denlinger, Igor Astsaturov, Michael Hall, John Hoffman] Background: Pathologic response to preoperative therapy is increasingly recognized as an important prognostic factor in solid tumors. The impact of pathologic response on survival in pancreatic adenocarcinoma is not well established. Methods: Data on 135 consecutive patients treated with chemoradiation followed by pancreatectomy for adenocarcinoma of the pancreatic head and/or body between July 1987 and May 2009 were reviewed. Histopathologic examination was performed in 107 patients to determine pathologic response, defined as minor (<50% fibrosis relative to residual neoplastic cells), partial (50-94% fibrosis), or major (95-100% fibrosis). Results: Minor, partial, and major pathologic response rates were 17% (n=18), 64% (n=68), and 19% (n=21), including a 7% (n=8) complete pathologic response rate. Pathologic response correlated with R0 resection (P=0.019), negative lymph nodes (P=0.006), and smaller tumor size (P=0.001). Median survival rates by pathologic response were as follows: 17months [95% confidence interval (CI), 0-36months] for minor response, 20months (95% CI, 17-23months) for partial response, and 66months (95% CI, 8-124months) for major response (minor versus partial response, P=not significant; partial versus major response, P<0.001). On multivariate analysis, major pathologic response was the only factor significantly associated with improved survival (P=0.025; hazard ratio, 2.26). Conclusions: Major pathologic response to preoperative therapy occurs in a minority of patients with pancreatic adenocarcinoma and is independently associated with prolonged survival. Society of Surgical Oncology, 2011 Chun Yun Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Cooper Harry Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Cohen Steven Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Konski Andre Department of Radiation Oncology, Wayne State University, Detroit, MI, USA aut Burtness Barbara Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Denlinger Crystal Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Astsaturov Igor Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Hall Michael Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Hoffman John Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3601-3607 1068-9265 18:13<3601 2011 18 10434 https://doi.org/10.1245/s10434-011-2086-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-2086-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chun Yun Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Cooper Harry Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Cohen Steven Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Konski Andre Department of Radiation Oncology, Wayne State University, Detroit, MI, USA aut NATIONALLICENCE 700 1- Burtness Barbara Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Denlinger Crystal Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Astsaturov Igor Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Hall Michael Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Hoffman John Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3601-3607 1068-9265 18:13<3601 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer